share_log

Cantor Fitzgerald Initiates Coverage On Atossa Therapeutics With Overweight Rating, Announces Price Target of $5

Benzinga ·  Sep 8, 2023 08:16

Cantor Fitzgerald analyst Louise Chen initiates coverage on Atossa Therapeutics (NASDAQ:ATOS) with a Overweight rating and announces Price Target of $5.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment